The 36-month beta value for ENSC is at 0.66. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ENSC is 14.62M, and currently, shorts hold a 43.47% of that float. The average trading volume for ENSC on November 18, 2024 was 27.52M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ENSC) stock’s latest price update
Ensysce Biosciences Inc (NASDAQ: ENSC)’s stock price has gone rise by 5.46 in comparison to its previous close of 0.64, however, the company has experienced a -8.16% decrease in its stock price over the last five trading days. accesswire.com reported 2024-11-12 that Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the third quarter ended September 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, “Our team has made significant progress in the third quarter, and we have line of sight to meaningful clinical initiatives to close out the year.
ENSC’s Market Performance
ENSC’s stock has fallen by -8.16% in the past week, with a monthly rise of 273.90% and a quarterly rise of 67.60%. The volatility ratio for the week is 13.12% while the volatility levels for the last 30 days are 28.47% for Ensysce Biosciences Inc The simple moving average for the past 20 days is 23.19% for ENSC’s stock, with a 18.04% simple moving average for the past 200 days.
ENSC Trading at 79.58% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.46% of loss for the given period.
Volatility was left at 28.47%, however, over the last 30 days, the volatility rate increased by 13.12%, as shares surge +277.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +79.25% upper at present.
During the last 5 trading sessions, ENSC fell by -8.16%, which changed the moving average for the period of 200-days by -54.70% in comparison to the 20-day moving average, which settled at $0.5442. In addition, Ensysce Biosciences Inc saw -36.75% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -6.29 for the present operating margin
- -3.38 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -7.91. The total capital return value is set at -0.96. Equity return is now at value -188.86, with -125.77 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -22.06. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -3.9.
Currently, EBITDA for the company is -10.72 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 9.33. The receivables turnover for the company is 0.56for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
In conclusion, Ensysce Biosciences Inc (ENSC) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
